Awards & Advancement

Epizyme appoints Matthew Ros chief operating officer

Friday, May 6, 2016

Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.

[Read More]

Formula Pharmaceuticals appoints Malcolm K. Brenner to scientific advisory board

Thursday, May 5, 2016

Formula Pharmaceuticals has appointed Dr. Malcolm K. Brenner, founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease.

[Read More]

CROMSOURCE opens North Carolina office, hires four

Monday, May 2, 2016

CROMSOURCE, an international CRO providing a comprehensive portfolio of services to the pharmaceutical, biotechnology and medical device industries, has appointed four senior executives to its management team. The appointments include Dr. Troy W. McCall as chief operating officer (COO), Debbie Kent as global head of TalentSource staffing solutions, Dr. Kerry Dyson as global head of Clinical Research Division and April McCall as vice president of Commercial Operations. Additionally, CROMSOURCE announced the expansion of its North American presence with the opening of an office in Research Triangle Park in North Carolina.

[Read More]